In vitro activity of gepotidacin (GSK2140944) against Neisseria gonorrhoeae

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 3, 2017, Pages

  Farrell, D J ^a,c   Sader, H S ^a   Rhomberg, P R ^a   Scangarella Oman, N E ^b   Flamm, R K ^a  

^a JMI LABORATORIES   (United States)

^b GLAXOSMITHKLINE   (United States)

^c Saskatchewan Disease Control Laboratory   (Canada)

Author keywords

Minimum bactericidal activity; Neisseria gonorrhoeae; Postantibiotic effect

Indexed keywords

AZITHROMYCIN; CEFTRIAXONE; CIPROFLOXACIN; GEPOTIDACIN; MOXIFLOXACIN; TETRACYCLINE; ACENAPHTHENE DERIVATIVE; ANTIINFECTIVE AGENT; DNA TOPOISOMERASE INHIBITOR; DNA TOPOISOMERASE IV; FUSED HETEROCYCLIC RINGS;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERICIDAL ACTIVITY; BROTH DILUTION; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG POTENTIATION; DRUG SCREENING; FRACTIONAL INHIBITORY CONCENTRATION INDEX; GONORRHEA; IN VITRO STUDY; MIC90; MINIMUM BACTERICIDAL CONCENTRATION; NEISSERIA GONORRHOEAE; NONHUMAN; PRIORITY JOURNAL; ANTAGONISTS AND INHIBITORS; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE;

ACENAPHTHENES; ANTI-BACTERIAL AGENTS; DNA TOPOISOMERASE IV; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GENE EXPRESSION; GONORRHEA; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; MICROBIAL SENSITIVITY TESTS; NEISSERIA GONORRHOEAE; TOPOISOMERASE INHIBITORS;

EID: 85014122938     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02047-16     Document Type: Article

References (24)

1. Centers for Disease Control and Prevention. 2014. 2013 sexually transmitted disease surveillance. Centers for Disease Control and Prevention, Atlanta, GA.
2. Fleming DT, Wasserheit JN. 1999. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Infect 75:3-17. https://doi.org/10.1136/sti.75.1.3.
3. Centers for Disease Control and Prevention. 2007. Update to CDC's sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections. MMWR Morb Mortal Wkly Rep 56:332-336.
4. Allen VG, Mitterni L, Seah C, Rebbapragada A, Martin IE, Lee C, Siebert H, Towns L, Melano RG, Low DE. 2013. Neisseria gonorrhoeae treatment failure and susceptibility to cefixime in Toronto, Canada. JAMA 309:163-170. https://doi.org/10.1001/jama.2012.176575.
5. Centers for Disease Control and Prevention. 2012. Update to CDC's sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections. MMWR Morb Mortal Wkly Rep 61:590-594.
6. Allen VG, Seah C, Martin I, Melano RG. 2014. Azithromycin resistance is coevolving with reduced susceptibility to cephalosporins in Neisseria gonorrhoeae in Ontario, Canada. Antimicrob Agents Chemother 58:2528-2534. https://doi.org/10.1128/AAC.02608-13.
7. Bax BD, Chan PF, Eggleston DS, Fosberry A, Gentry DR, Gorrec F, Giordano I, Hann MM, Hennessy A, Hibbs M, Huang J, Jones E, Jones J, Brown KK, Lewis CJ, May EW, Saunders MR, Singh O, Spitzfaden CE, Shen C, Shillings A, Theobald AJ, Wohlkonig A, Pearson ND, Gwynn MN. 2010. Type IIA topoisomerase inhibition by a new class of antibacterial agents. Nature 466:935-940. https://doi.org/10.1038/nature09197.
8. Biedenbach DJ, Bouchillon SK, Hackel M, Miller LA, Scangarella-Oman NE, Jakielaszek C, Sahm DF. 2016. In vitro activity of gepotidacin, a novel triazaacenaphthylene bacterial topoisomerase inhibitor, against a broad spectrum of bacterial pathogens. Antimicrob Agents Chemother 60:1918-1923. https://doi.org/10.1128/AAC.02820-15.
9. Clinical and Laboratory Standards Institute. 2015. M07-A10: methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 10th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
10. Jones RN, Fedler KA, Scangarella-Oman NE, Ross JE, Flamm RK. 2016. Multicenter investigation of gepotidacin (GSK2140944) agar dilution quality control determinations for Neisseria gonorrhoeae ATCC 49226. Antimicrob Agents Chemother 60:4404-4406. https://doi.org/10.1128/AAC.00527-16.
11. Clinical and Laboratory Standards Institute. 2016. M100-S26. Performance standards for antimicrobial susceptibility testing: 26th informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA.
12. Black MT, Stachyra T, Platel D, Girard AM, Claudon M, Bruneau JM, Miossec C. 2008. Mechanism of action of the antibiotic NXL101, a novel nonfluoroquinolone inhibitor of bacterial type II topoisomerases. Antimicrob Agents Chemother 52:3339-3349. https://doi.org/10.1128/AAC.00496-08.
13. Lahiri SD, Kutschke A, McCormack K, Alm RA. 2015. Insights into the mechanism of inhibition of novel bacterial topoisomerase inhibitors from characterization of resistant mutants of Staphylococcus aureus. Antimicrob Agents Chemother 59:5278-5287. https://doi.org/10.1128/AAC.00571-15.
14. Nayar AS, Dougherty TJ, Reck F, Thresher J, Gao N, Shapiro AB, Ehmann DE. 2015. Target-based resistance in Pseudomonas aeruginosa and Escherichia coli to NBTI 5463, a novel bacterial type II topoisomerase inhibitor. Antimicrob Agents Chemother 59:331-337. https://doi.org/10.1128/AAC.04077-14.
15. Dougherty TJ, Nayar A, Newman JV, Hopkins S, Stone GG, Johnstone M, Shapiro AB, Cronin M, Reck F, Ehmann DE. 2014. NBTI 5463 is a novel bacterial type II topoisomerase inhibitor with activity against gram-negative bacteria and in vivo efficacy. Antimicrob Agents Chemother 58:2657-2664. https://doi.org/10.1128/AAC.02778-13.
16. Ruiz J, Jurado A, Garcia-Mendez E, Marco F, Aguilar L, Jimenez de Anta MT, Vila J. 2001. Frequency of selection of fluoroquinolone-resistant mutants of Neisseria gonorrhoeae exposed to gemifloxacin and four other quinolones. J Antimicrob Chemother 48:545-548. https://doi.org/10.1093/jac/48.4.545.
17. Jeverica S, Golparian D, Hanzelka B, Fowlie AJ, Maticic M, Unemo M. 2014. High in vitro activity of a novel dual bacterial topoisomerase inhibitor of the ATPase activities of GyrB and ParE (VT12-008911) against Neisseria gonorrhoeae isolates with various high-level antimicrobial resistance and multidrug resistance. J Antimicrob Chemother 69:1866-1872. https://doi.org/10.1093/jac/dku073.
18. Takei M, Yamaguchi Y, Fukuda H, Yasuda M, Deguchi T. 2005. Cultivation of Neisseria gonorrhoeae in liquid media and determination of its in vitro susceptibilities to quinolones. J Clin Microbiol 43:4321-4327. https://doi.org/10.1128/JCM.43.9.4321-4327.2005.
19. Clinical and Laboratory Standards Institute. 1999. M26-A: methods for determining bactericidal activity of antimicrobial agents; approved guideline. Clinical and Laboratory Standards Institute, Wayne, PA.
20. Leber AL (ed). 2016. Antimicrobial susceptibility testing, p. 5.16.1-5.16.21. Clinical microbiology procedures handbook, 4th ed. ASM Press, Washington, DC.
21. Leber AL (ed). 2016. Antimicrobial susceptibility testing, p. 5.14.2.1-5.14.2.12. Clinical microbiology procedures handbook, 4th ed. ASM Press, Washington, DC.
22. Odenholt-Tornqvist I. 1993. Studies on the postantibiotic effect and the postantibiotic sub-MIC effect of meropenem. J Antimicrob Chemother 31:881-892. https://doi.org/10.1093/jac/31.6.881.
23. Odenholt-Tornqvist I, Lowdin E, Cars O. 1992. Postantibiotic sub-MIC effects of vancomycin, roxithromycin, sparfloxacin, and amikacin. Antimicrob Agents Chemother 36:1852-1858. https://doi.org/10.1128/AAC.36.9.1852.
24. Spangler SK, Lin G, Jacobs MR, Appelbaum PC. 1998. Postantibiotic effect and postantibiotic sub-MIC effect of levofloxacin compared to those of ofloxacin, ciprofloxacin, erythromycin, azithromycin, and clarithromycin against 20 pneumococci. Antimicrob Agents Chemother 42:1253-1255.